Windtree Therapeutics Company Insiders
WINT Stock | USD 0.61 0.05 8.89% |
Windtree Therapeutics employs about 12 people. The company is managed by 12 executives with a total tenure of roughly 28 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Breaking down Windtree Therapeutics' management performance can provide insight into the firm performance.
Craig Fraser CEO President CEO, Director |
John Tattory President CFO, Senior Vice President |
Windtree |
Windtree Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4476) % which means that it has lost $0.4476 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.508) %, meaning that it created substantial loss on money invested by shareholders. Windtree Therapeutics' management efficiency ratios could be used to measure how well Windtree Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.98 in 2024. Return On Capital Employed is likely to drop to -0.65 in 2024. Liabilities And Stockholders Equity is likely to gain to about 42.3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 3.8 M in 2024.Common Stock Shares Outstanding is likely to gain to about 231 K in 2024, whereas Net Loss is likely to drop (63.9 M) in 2024.
Windtree Therapeutics Workforce Comparison
Windtree Therapeutics is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 46.0. Windtree Therapeutics adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Windtree Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Windtree Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Windtree Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Windtree Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Craig Fraser over a week ago Acquisition by Craig Fraser of 500 shares of Windtree Therapeutics at 2.4587 subject to Rule 16b-3 | ||
Bioengine Capital Inc. over a month ago Disposition of 249004 shares by Bioengine Capital Inc. of Windtree Therapeutics at 12.15 subject to Rule 16b-3 | ||
Craig Fraser over a month ago Acquisition by Craig Fraser of 5431 shares of Windtree Therapeutics at 0.9099 subject to Rule 16b-3 | ||
Huang James over two months ago Acquisition by Huang James of 1112308 shares of Windtree Therapeutics at 0.1411 subject to Rule 16b-3 | ||
Latkin Jed over three months ago Insider Trading | ||
Craig Fraser over three months ago Acquisition by Craig Fraser of 2000 shares of Windtree Therapeutics at 0.9799 subject to Rule 16b-3 | ||
Craig Fraser over six months ago Acquisition by Craig Fraser of 3000 shares of Windtree Therapeutics at 1.9 subject to Rule 16b-3 | ||
Jamie McAndrew over six months ago Disposition of 220 shares by Jamie McAndrew of Windtree Therapeutics at 272.0 subject to Rule 16b-3 |
Windtree Therapeutics Notable Stakeholders
A Windtree Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Windtree Therapeutics often face trade-offs trying to please all of them. Windtree Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Windtree Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Craig Fraser | President CEO, Director | Profile | |
John Tattory | CFO, Senior Vice President | Profile | |
Steven Simonson | Senior Vice President and Chief Development Officer | Profile | |
Eric MBA | Senior COO | Profile | |
Jamie McAndrew | Controller, VP | Profile | |
George Cox | Vice Operations | Profile | |
Pratap Paruchuru | Executive Development | Profile | |
Ronald Dundore | Ex Quality | Profile | |
MHS MD | Senior Officer | Profile | |
Tracy Rarick | Head Management | Profile | |
Diane Esq | Sr Counsel | Profile | |
John CPA | CFO, VP | Profile |
About Windtree Therapeutics Management Performance
The success or failure of an entity such as Windtree Therapeutics often depends on how effective the management is. Windtree Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Windtree management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Windtree management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (2.84) | (2.98) | |
Return On Capital Employed | (0.62) | (0.65) | |
Return On Assets | (0.63) | (0.66) | |
Return On Equity | (5.98) | (5.68) |
Please note, the imprecision that can be found in Windtree Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Windtree Therapeutics. Check Windtree Therapeutics' Beneish M Score to see the likelihood of Windtree Therapeutics' management manipulating its earnings.
Windtree Therapeutics Workforce Analysis
Traditionally, organizations such as Windtree Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Windtree Therapeutics within its industry.Windtree Therapeutics Manpower Efficiency
Return on Windtree Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.7M | |
Net Loss Per Executive | 1.7M | |
Working Capital Per Employee | 115.2K | |
Working Capital Per Executive | 115.2K |
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.